A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.

A new randomized clinical trial from investigators at Mass General Brigham's Neuroscience Institute and Department of Psychiatry suggests that using personalized brain imaging to guide transcranial magnetic ...